Semaglutide and Its Role in Kidney Disease Management
Semaglutide, commonly known by its brand names Ozempic or Wegovy, is primarily recognized for its role in weight loss. However, recent research has uncovered another significant benefit of this medication: its potential to slow the progression of kidney disease in individuals with type 2 diabetes and chronic kidney disease.
A new analysis published today highlights that people with type 2 diabetes and chronic kidney disease who took semaglutide once a week experienced improved kidney function and better survival rates. This benefit was observed even in those with a history of heart attacks, strokes, or heart failure. The findings build upon earlier studies that showed the drug’s “consistent benefits” in reducing the risk of heart attacks, strokes, and death due to cardiovascular causes in similar patient groups.
Katherine Tuttle, the lead researcher for the new analysis and professor of medicine at the University of Washington, described semaglutide as a “highly kidney protective therapy.” She emphasized that while reducing the risks of major adverse cardiovascular events is crucial for individuals with heart disease, staying alive without the need for dialysis is equally important. According to Tuttle, patients with heart disease or high heart disease risk are more likely to remain alive, retain their kidney function, and avoid dialysis when treated with semaglutide.
Understanding the Mechanism
Semaglutide belongs to a class of drugs called GLP-1 receptor agonists, originally developed to help manage blood sugar levels in people with type 2 diabetes. These drugs mimic the activity of glucagon-like peptide 1 (GLP-1), a natural hormone that regulates glucose metabolism.
In recent years, GLP-1 mimicking medicines have gained popularity as weight-loss treatments because they slow digestion and help individuals feel full for longer periods. James Tang, a kidney specialist and transplant physician at St Vincent’s Hospital, noted that while there are some knowns about how semaglutide helps slow kidney disease progression, the exact mechanism remains unclear.
Tang explained that type 2 diabetes, chronic kidney disease, heart disease, and obesity are all interconnected. By addressing the impact of obesity and type 2 diabetes on the body, there is a positive “flow on effect” to the kidneys. He emphasized that treating the root cause of kidney disease is essential, and mitigating its progression involves optimizing factors like diabetes management, blood pressure control, and weight management.
However, Tang acknowledged that more research is needed to understand whether semaglutide alone improves kidney health or if its benefits stem from its broader effects on metabolic conditions.
Prevalence and Treatment in Australia
According to the latest estimates, about 2.7 million Australian adults have biomedical signs of chronic kidney disease, although the condition is often diagnosed in its advanced stages when symptoms become apparent. Last year, the Therapeutic Goods Administration approved the use of Ozempic to help reduce kidney disease progression in individuals with type 2 diabetes and chronic kidney disease.
Study Limitations and Funding
Professor Tuttle’s study used data from the FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial, which was funded by pharmaceutical company Novo Nordisk. Novo Nordisk is the manufacturer of Ozempic and Wegovy.
Natalie Raffoul, a senior manager for healthcare programs and clinical strategy at the Heart Foundation, noted that industry sponsorship of clinical trials involving GLP-1 medicines is common. She stated that such conflicts are typically managed through independent governance groups. However, she pointed out that most of the FLOW trial’s participants were older, male, and white, which limits the generalizability of the findings. Professor Tuttle acknowledged the need for greater racial and ethnic diversity and longer study duration to improve statistical power.
Despite these limitations, Raffoul and Tang agreed that the study provided valuable evidence supporting the potential benefits of semaglutide for high-risk populations.
Broader Health Implications
The Heart Foundation recently released new guidelines recommending semaglutide for weight loss in individuals with established cardiovascular disease, such as a history of heart attack, to reduce future risk. Raffoul described this as a timely move, given the growing evidence that these medicines not only help manage overweight and obesity but also reduce the risk of heart attacks and other cardiovascular events.
However, Raffoul highlighted that some key questions remain unanswered. For instance, it is unclear whether the heart health improvements seen in patients are due to weight loss or the direct effects of the drug. Weight loss itself can have beneficial effects on cardiovascular risk factors such as blood pressure and cholesterol.
She also mentioned that ongoing studies are investigating whether semaglutide has independent anti-inflammatory effects that could further improve heart health outcomes. Raffoul emphasized that Ozempic-like drugs require a prescription and are not without risks or side effects. She advised that patients should only take these medications if the benefits outweigh the potential risks.
Conclusion
As research continues to uncover the multifaceted benefits of semaglutide, its role in managing both diabetes and kidney disease becomes increasingly significant. While more studies are needed to fully understand its mechanisms and long-term effects, current evidence suggests that it offers promising therapeutic options for high-risk populations.
